TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations
ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here.
Tg Therapeutics Inc. (TGTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Walleye Capital Will England | 190,302 | $10,455,192 | +9331% | 0.04% |
| 2. | Navellier & Associates Louis Navellier | 29,290 | $1,609,193 | 0.13% | |
| 3. | Iridian Asset Management David Cohen And Harold Levy | 27,689 | $1,521,234 | -64% | 0.52% |
| 4. | 22,700 | $1,247,138 | +59% | 0% | |
| 5. | Winton Capital Management David Harding | 15,677 | $861,294 | -58% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.13 | 100,000 | $1,013,000.00 | 12,073,021 | 2023-08-11 | Filing | |
| $10.64 | 9,000 | $95,760.00 | 201,848 | 2023-01-06 | Filing | |
| $7.04 | 50,000 | $351,750.00 | 12,878,185 | 2019-06-26 | Filing | |
| $6.53 | 114,855 | $750,003.15 | 5,114,855 | 2015-02-17 | Filing | |
| $3.43 | 10,000 | $34,300.00 | 7,839,471 | 2013-12-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.57 | 5,000 | $162,850.00 | 223,816 | 2025-11-24 | Filing | |
| $32.24 | 20,852 | $672,268.48 | 94,061 | 2025-09-11 | Filing | |
| $36.94 | 10,000 | $369,400.00 | 228,816 | 2025-06-13 | Filing | |
| $28.53 | 10,021 | $285,939.21 | 660,611 | 2025-01-06 | Filing | |
| $30.29 | 11,337 | $343,443.08 | 670,632 | 2025-01-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,050,045 | $1,211,429,475 | 0.02% | |
| 2. | 7,786,471 | $427,788,717 | 0.01% | |
| 3. | 2,600,123 | $142,850,758 | 0.88% | |
| 4. | 1,785,951 | $98,120,148 | 0.09% | |
| 5. | 900,482 | $49,472,499 | 0.01% |
News See All
10 Best Performing American Stocks in June 2026
Fidelity says “Market breadth has broadly remained strong” and “unrelenting corporate earnings growth has underpinned stocks.” That suggests some recent rallies are happening in a market still...
Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?
Is TGTX a good stock to buy? We came across a bullish thesis on TG Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on TGTX.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2026 Earnings Call Transcript
Operator: Greetings, and welcome to the TG Therapeutics First Quarter Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)
On February 26, TG Therapeutics Inc. (NASDAQ:TGTX) reported Q4 revenue of $192.6 million compared with consensus estimates of $193.3 million.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings
TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 13 Most Profitable Growth Stocks to Buy Right Now. Alec Stranahan of Bank of America reaffirmed a Sell rating on TG Therapeutics, Inc.
13 Most Profitable Growth Stocks to Buy Right Now
Equity markets remain volatile amid geopolitical uncertainties.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the TG Therapeutics Fourth Quarter and Year-End 2025 Earnings Call. [Operator Instructions] Please note, this conference is being recorded.
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025
TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the best cheap biotech stocks to buy now. TG Therapeutics, Inc. (NASDAQ:TGTX) released financial results for fiscal Q4 and full year 2025 on February 26.